NeuroMab™ Anti-NOTCH3 Antibody(NRP-0422-P1871)

Figure 1 shows the binding of the 28042 antibody to Fc fusion proteins of the extracellular domains of Notch1, Notch2 and Notch3, as observed by surface plasmon resonance (SPR).

Binding was measured at three different dilutions. The results demonstrate that the 28042 antibody has high binding affinity to Notch3, while the 28042 antibody has no significant binding to Notch1 or Notch2.

Figure 2 shows the binding of the 28042 antibody to cell surface human Notchl, human Notch2, human Notch3 and murine Notch3 as observed by FACS.

The results demonstrate that the 28042 antibody binds both human and murine Notch3, whereas the 28042 antibody does not significantly bind Notch1 or Notch2.

Figure 3 is a Western blot showing the level of inhibition of Jag1-induced Notch3 activation by the 28042 antibody compared to other antibodies, as assessed by the extent of intracellular domain cleavage of mNotch3 expressed in FlpIn™ cells.

Figure 4 is a Western blot showing the level of inhibition of DLL4-induced human Notch3 receptor activation as assessed by Notch3 intracellular domain cleavage in NCI-H838 cells plated on ligand in the presence of 28042 antibody and other antibodies of.

Figure 5 shows the inhibition of ligand-induced Notch3 receptor activation as determined by Notch3 intracellular domain cleavage.

Graph is a Western blot showing the level of inhibition of Jag1, Jag2, and DLL4-induced Notch3 activation by the 28042 antibody, as assessed by the extent of intracellular domain cleavage of murine Notch3 expressed in FlpIn™ cells.

Figure 6 is a dose response curve based on a human Notch3 reporter assay showing that the 28042 antibody inhibits functional Notch3 activation as measured by Notch3-dependent reporter expression in the presence of the Fc-binding ligand Jag2 (Jag2-Fc).

The graph shows the inhibition of Jag2-Fc-stimulated reporter activity (% Inhibition) by antibody the 28042 antibody in stably transduced cells as a function of the amount of the 28042 antibody.

Figure 7 shows the inhibition of tumor growth by the 28042 antibody in a Notch3-mediated mouse tumor model.

Graph showing the change in tumor volume over time (in days) in mice treated with hIgG or 28042 antibodies. The 28042 antibody showed significant tumor growth inhibition compared to an IgG control.

Figure 8 shows the inhibition of tumor growth by the 28042 antibody in a Notch3-mediated mouse tumor model.

Graph depicts Western blot of harvested tumor lysates using a Notch3 C-terminal-specific antibody to detect the extent of Notch intracellular domain cleavage. β-tubulin was used as a loading control.